Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Platelet Rich Fibrin With 1% Metformin Gel for Treatment of Intrabony Defects
- Conditions
- Periodontitis
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Government Dental College and Research Institute, Bangalore
- Target Recruit Count
- 120
- Registration Number
- NCT02283554
A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 30
- Registration Number
- NCT02279758
- Locations
- 🇧🇷
Instituto do Cancer do Estado de São Paulo, Sao Paulo, SP, Brazil
Trial With Metformin in Women With Polycystic Ovary Syndrome
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Herning Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT02280057
- Locations
- 🇩🇰
Gynecology Dept. Herning Hospital, Herning, Denmark
Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
- Conditions
- Stage 0 Breast CarcinomaBreast NeoplasmsStage I Breast CarcinomaStage II Breast CarcinomaStage III Breast Carcinoma
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Katherine D. Crew
- Target Recruit Count
- 19
- Registration Number
- NCT02278965
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Maasstad Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02275845
- Locations
- 🇳🇱
Maasstad Ziekenhuis, Rotterdam, Netherlands
Use of Metformin in Treatment of Childhood Obesity
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- University of Colombo
- Target Recruit Count
- 339
- Registration Number
- NCT02274948
- Locations
- 🇱🇰
Lions Club of Negombo Host, Negombo, Western Province, Sri Lanka
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
- Conditions
- Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2
- Registration Number
- NCT02274740
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02266472
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Metformin in Kidney Disease
- Conditions
- Cardiovascular DiseaseChronic Kidney DiseaseMetabolic Syndrome
- Interventions
- Drug: PlaceboDrug: metformin
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 125
- Registration Number
- NCT02252081
- Locations
- 🇺🇸
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
- Conditions
- HealthyDiabetes
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT02249910
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.